Am­gen inks dis­cov­ery deal with Hum­ming­bird; Mer­ck gains pri­or­i­ty re­view for Ebo­la vac­cine

Am­gen has en­list­ed Hum­ming­bird Bio­science on a new an­ti­body dis­cov­ery pact, turn­ing over some nov­el tar­gets to see if the small­er play­er’s sys­tems …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.